What's Hot
View all perspectives
Aurelie Najm AurelieRheumo
3 years 6 months ago
In a new scientific era dominated by high throughput technologies, statistical analysis is at least as important than samples quality. Different data modeling strategies applicable to ScRNASeq discussed by Dr @YvanSaeys in the #EULAR2021 Investigative Rheumatology. @Rheumnow https://t.co/eMcNfWIxM2
Aurelie Najm AurelieRheumo
3 years 6 months ago
EUSTAR database: in 474 patients w/ no baseline ILD, t0 DLCO value<80% predicted ILD on HRCT at 2years w/ OR 3.1 [1.49-6.40]p=0.0023 while t0 FVC value<80% didn't reach statistical significance OR 1.95 p=0.13. To be confirmed in prospective studies! @RheumNow #EULAR2021 #POS0317 https://t.co/haNlN0OfX4
Aurelie Najm AurelieRheumo
3 years 6 months ago
COVAX Registry: 1519 patients w/ 51% IA, 45% CsDMARDs, 36% bioDMARDs, 31% GCs; vaccinated with Pfizer, AZ or Moderna. Overall, very reassuring safety profile. 5% flares. Efficacy to trigger AB response needs to be further assessed.
@pedrommcmachado #LB0004 @Rheumnow #EULAR2021 https://t.co/1dSfOJALzf
Richard Conway RichardPAConway
3 years 6 months ago
Dr Furer on immunogenicity of Pfizer vaccine in RMD. Most good responses. GC, rituximab, MMF, abatacept blunt response. @RheumNow #EULAR2021 Abstr#LB0003 https://t.co/Lq4kx7B5bJ
Janet Pope Janetbirdope
3 years 6 months ago
Reader beware: Interpretation of relative effectiveness & safety of JAKi vs bDMARDs in real world data
POS0093 JAK-pot
heterogeneity between countries with variable safety @RheumNow @eular_org #EULAR2021
19 registries >700 JAK RA Rx markedly diff d/c due to AEs https://t.co/jFgN8NVx8v
Janet Pope Janetbirdope
3 years 6 months ago
Comparative effectiveness in RWD of retention of #tofacitinib vs #bDMARDs Equal d/c of Tofa and TNFI in RA in OBRI and Rhumatdata, Canadian databases
OP0179 #EULAR2021 @RheumNow @eular_org
1/3 in each group d/c Rx. Some other studies show retention better on JAKi than bDMARDs.
Janet Pope Janetbirdope
3 years 6 months ago
Real world data comparing #TNFi to nonTNFi Effectiveness in US RISE registry >16000 pts OP0117 No diff in DAS in RA between TNFi and non TNFi use
Diff ethnicities may make a difference & SES factors. So interpretation of diff registries may show diff results @RheumNow @eular_org
Janet Pope Janetbirdope
3 years 6 months ago
More zoster but ⬆️serious infections also in >3700 RA pts from BIOBASDER comparing #JAKi to #bDMARD. ? Due to later line Rx w JAKi? This is diff from some registries/ real world data wher other than HZ, serious infections are equal. OP0123 @RheumNow @eular_org
Janet Pope Janetbirdope
3 years 6 months ago
Smog makes arthritis flare! Study of air pollution & flares in 888 RA pts. With higher air pollution, 70% ⬆️risk of ⬆️CRP. Pts Nitric oxide exposed cumulative over 60 days had higher DAS but <5% of drug changes explained by air pollution. OP0178 @RheumNow @eular_org #EULAR2021
Janet Pope Janetbirdope
3 years 6 months ago
Comorbidities in RA ⬇️response at 6 months with first bDMARD! 501 pts with 1098 bDMARDs Rx. Presence of baseline comorbidities predicted poor response & worse if ⬆️comorbidities. OP0299 @eular_org @RheumNow #EULAR2021 https://t.co/P9pYf93NXw
Janet Pope Janetbirdope
3 years 6 months ago
Make sure #SLE pts with > 5 yrs of #Plaquenil get their regular FULL retinal screening. Retinal toxicity 6.8% for HCQ>5 years. risks seem to be cumulative dose, higher daily dose in users >5 yrs OP0133 @eular_org @RheumNow #EULAR2021 https://t.co/mVCdMxA2LX
Janet Pope Janetbirdope
3 years 6 months ago
Does she or doesn’t she have swollen jts during telemed call? Referred pts with suspected IA marked swollen jts on a mannequin. In 1637 pts 3/4 marked 1 or more jts ~41% had SJC by Rheum exam. Sens 87% but spec only 31%. Reasonable screen. POS1418 @RheumNow @eular_org #EULAR2021
Janet Pope Janetbirdope
3 years 6 months ago
What costs more in #SLE? Hospitalization for lupus nephritis or for mental health? @RheumNow @eular_org #EULAR2021 POS0304
Janet Pope Janetbirdope
3 years 6 months ago
Can I use #Rituximab during #pandemic? Ritux blunts response to #SARSCoV2 #vaccine LB0003 & worse outcomes vs other Rheum meds (also pred) from Global Rheum Alliance OP0006 but pts on Rituximab have worse disease ~ANCA vasculitis& diff to Rx RA. @RheumNow @eular_org #EULAR2021
Janet Pope Janetbirdope
3 years 6 months ago
Pts will achieve LESS remission in RA, PsA & SpA if high pain catastrophizing score ~50% less remission in RA, even less in PsA (but not stat signif in PsA) ~75% less in axSpA. OP0089 @RheumNow @eular_org #EULAR2021
Poster Hall